Tesofensine
InvestigationalAlso known as: NS2330, TE
MetabolicLast reviewed: April 28, 2026
A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's that showed remarkable weight loss in Phase 2 trials. Now being developed specifically for obesity.
Mechanism of Action
Inhibits reuptake of serotonin, norepinephrine, and dopamine, reducing appetite and increasing energy expenditure through central nervous system modulation. Different mechanism than GLP-1 agonists.
Common Uses
- Weight management (investigational)
- Appetite suppression
- Metabolic rate enhancement
Known Risks
- Increased heart rate
- Dry mouth
- Insomnia
- Constipation
- Potential cardiovascular concerns
- Not yet approved — full safety profile unknown
Regulatory Status
Phase 3 clinical trials ongoing. Phase 2 showed up to 12.8% body weight loss at 24 weeks. Approved in Mexico (2024). Not FDA-approved in the US.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Oral capsule
Typical Dose
0.25–0.5 mg
Frequency
Once daily
Cycle Length
Ongoing
Not commercially available in the US. Some compounding pharmacies may offer it in a gray area. Verify legal status before use.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.